Health technology assessments by the National Institute for Health and Clinical Excellence : a qualitative study / Michael Schlande ; forewords by Peter S. Jensen and Panos G. Kanavos.Material type: TextSeries: SpringerInnovation and valuation in health care: Publisher: New York : Springer, c2007Description: 1 online resource (xix, 245 p.) : illISBN: 9780387719962; 0387719962Subject(s): National Institute for Clinical Excellence (Great Britain) | Medical technology -- Evaluation | Attention-deficit hyperactivity disorder -- Diagnosis | Attention-deficit hyperactivity disorder -- TreatmentAdditional physical formats: Print version:: Health technology assessments by the National Institute for Health and Clinical Excellence.LOC classification: R855.3 | .S34 2007Online resources: Click here to view this ebook.
|Item type||Current location||Call number||URL||Status||Date due||Barcode|
|Electronic Book||UT Tyler Online Online||R855.3 .S34 2007 (Browse shelf)||http://ezproxy.uttyler.edu:2048/login?url=http://dx.doi.org/10.1007/978-0-387-71996-2||Available||ocn232363297|
Includes bibliographical references (p. 207-238) and index.
Introduction -- A note on objectives and methods -- NICE [National Institute for Health and Clinical Excellence] appraisal process -- NICE appraisal of ADHD treatments -- NICE appraisal of ADHD treatment options: a critique -- Discussion and implications -- Which way forward?
Appendices: Abbreviations and use of terminology -- Critical gaps of assessment -- Consistency issues associated with NICE assessment.
Description based on print version record.
Author notes provided by Syndetics
Michael Schlander is founder and chairman of the independent Institute for Innovation & Valuation in Health Care (InnoValHC), a non-profit, non-partisan scientific organization dedicated to research related to the utilization, effectiveness, efficiency, and quality of health care, with particular emphasis on novel approaches of service provision. He teaches health economics and innovation management at the University of Duisburg-Essen (Faculty of Medicine, since 2005) and at the University of Applied Economic Sciences Ludwigshafen, Germany (since 2002). Prior to his university appointment, he spent fifteen years in senior positions with international pharmaceutical companies in Germany, Belgium, and the United States, and six years in experimental brain research and clinical neurology at German universities.